Evaluation of vancomycin individualized model-based dosing approach in neonates

Area of Science:

• Pharmacology
• Neonatal Medicine
• Infectious Diseases

Background:

• Vancomycin is essential for treating methicillin-resistant staphylococcal infections in neonates.
• Optimal vancomycin dosing in neonates remains a challenge.
• Population pharmacokinetic (PopPK) modeling offers a tool for optimizing initial dosing.

Purpose of the Study:

• To evaluate a PopPK model-based approach for vancomycin dosing in neonates.
• To assess the model's ability to achieve the target AUC0-24 of 400 mg·h/L.
• To implement the model as an accessible Excel calculator for personalized neonatal vancomycin dosing.

Main Methods:

• Developed an Excel calculator based on a published neonatal PopPK model.
• Evaluated the calculator using retrospective neonatal data.
• Compared the probability of achieving the target AUC0-24 with the model-based approach versus standard dosing references.

Main Results:

• The analysis included 225 neonates.
• The model-based approach achieved the target AUC0-24 in 89% of neonates.
• This significantly outperformed standard dosing references, which achieved the target in 11%-59% (p < 0.01).

Conclusions:

• Personalized vancomycin dosing calculators based on PopPK models are effective.
• This approach shows promise for improving initial vancomycin dosing in neonates.
• The Excel calculator is easily applicable in routine clinical practice.